Get the Stockscreener App
0.00
100.00%
-0.55
After Hours:
.55
0.55
+
Marinus Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$0.55
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$30.37M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
0.00
EPS:
-2.63
Net Cash Flow:
$-118.12M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.41
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Compare MRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.00 | 30.37M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-16-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-15-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Armenian Reporter
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus pharmaceuticals director sells shares for $864 - MSN
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Make Informed Decisions with Marinus Pharmaceuticals Inc (MRNS) Stock Updates - The News Heater
Taking on analysts’ expectations and winning: Marinus Pharmaceuticals Inc (MRNS) - SETE News
Marinus Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your RightsMRNS - ACCESS Newswire
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact Levi & Korsinsky about pending Class ActionMRNS - ACCESS Newswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Morgan Stanley's Strategic Acquisition of Marinus Pharmaceuticals Shares - GuruFocus.com
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Brokerages - Defense World
JPMorgan Chase & Co. Buys 126,752 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Vanguard Group Inc Reduces Holdings in Marinus Pharmaceuticals I - GuruFocus.com
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UPCOMING MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Assenagon Asset Management S.A. - Defense World
Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis - MarketBeat
Marinus pharmaceuticals director sells shares for $864 By Investing.com - Investing.com Canada
Immedica to buy Marinus Pharmaceuticals for $151m - MSN
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene - Barchart
Fragile X Syndrome Market Predicted to See Upsurge Through 2034, - openPR
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action - The Malaysian Reserve
Marinus plummets 78% as phase 3 interim analysis of ganaxolone disappoints - MSN
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know - MSN
Beryl Capital Management LLC Acquires Significant Stake in Marin - GuruFocus.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Marinus Pharmaceuticals, Inc.MRNS - Kilgore News Herald
Immedica Pharma AB’s Acquisition of Marinus Pharmaceuticals - Global Legal Chronicle
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc.MRNS - Business Wire
Immedica acquires Marinus in $151 million deal - The Pharma Letter
Marinus Therapeutics in Radnor Acquired by Swedish Company - MSN
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MSN
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):